Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Orexigen Therapeutics Company Profile (NASDAQ:OREX)

Consensus Ratings for Orexigen Therapeutics (NASDAQ:OREX) (?)
Ratings Breakdown: 2 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $8.92 (75.35% upside)

Analysts' Ratings History for Orexigen Therapeutics (NASDAQ:OREX)
Show:
DateFirmActionRatingPrice TargetDetailsShare
7/16/2014ZacksReiterated RatingNeutral -> Neutral$5.50ViewTweet This Rating  Share This Rating on StockTwits
4/24/2014Wells Fargo & Co.Initiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
1/10/2014WallachBeth CapitalInitiated CoverageBuy$9.00ViewTweet This Rating  Share This Rating on StockTwits
11/27/2013JPMorgan Chase & Co.Reiterated RatingOverweight -> Positive$12.00ViewTweet This Rating  Share This Rating on StockTwits
11/26/2013Credit SuisseLower Price TargetOutperform$11.00 -> $10.00ViewTweet This Rating  Share This Rating on StockTwits
10/4/2013Jefferies GroupReiterated RatingHold$7.00ViewTweet This Rating  Share This Rating on StockTwits
10/3/2013Cowen and CompanyInitiated CoverageOutperform -> Outperform$10.00ViewTweet This Rating  Share This Rating on StockTwits
6/21/2013Bank of AmericaReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
1/3/2013Piper JaffrayInitiated CoverageOverweight$10.00ViewTweet This Rating  Share This Rating on StockTwits
10/23/2012Jefferies GroupBoost Price TargetHold$5.00 -> $6.00ViewTweet This Rating  Share This Rating on StockTwits
9/6/2012Credit SuisseInitiated CoverageOutperform$13.00ViewTweet This Rating  Share This Rating on StockTwits
8/8/2012Leerink SwannReiterated RatingOutperformViewTweet This Rating  Share This Rating on StockTwits
(Data available from 7/31/2012 forward)